JO3684B1 - صور متبلرة من الملح ثنائي الصوديوم لحمض n-(5-كلورو ساليسلويل)-8-امينو كابريليك - Google Patents

صور متبلرة من الملح ثنائي الصوديوم لحمض n-(5-كلورو ساليسلويل)-8-امينو كابريليك

Info

Publication number
JO3684B1
JO3684B1 JOP/2006/0324A JOP20060324A JO3684B1 JO 3684 B1 JO3684 B1 JO 3684B1 JO P20060324 A JOP20060324 A JO P20060324A JO 3684 B1 JO3684 B1 JO 3684B1
Authority
JO
Jordan
Prior art keywords
chlorosalicyloyl
sodium salt
polymorphic forms
crystalline polymorphic
aminocaprylic acid
Prior art date
Application number
JOP/2006/0324A
Other languages
English (en)
Inventor
C O`Toole Doris
P Corvino Joanne
Majuru Shingai
Dhoot Nikhil
Elliot Bay William
Dinh Steven
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37889458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3684(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Application granted granted Critical
Publication of JO3684B1 publication Critical patent/JO3684B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بصور متعددة الشكل البلوري من الملح ثنائي الصوديوم لحمض N-(5-كلورو ساليسلويل)-8-امينو كابريليك، وتركيبات صيدلانية تحتوي عليها وطرق لتحضيرها وطرق لتسهيل نقل العوامل النشطة باستخدامها.
JOP/2006/0324A 2005-09-19 2006-09-19 صور متبلرة من الملح ثنائي الصوديوم لحمض n-(5-كلورو ساليسلويل)-8-امينو كابريليك JO3684B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71882905P 2005-09-19 2005-09-19

Publications (1)

Publication Number Publication Date
JO3684B1 true JO3684B1 (ar) 2020-08-27

Family

ID=37889458

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0324A JO3684B1 (ar) 2005-09-19 2006-09-19 صور متبلرة من الملح ثنائي الصوديوم لحمض n-(5-كلورو ساليسلويل)-8-امينو كابريليك

Country Status (19)

Country Link
US (3) US8026392B2 (ar)
EP (1) EP1937627A4 (ar)
JP (1) JP2009508875A (ar)
KR (1) KR20080049128A (ar)
CN (2) CN105641686A (ar)
AR (1) AR058053A1 (ar)
AU (1) AU2006292337B8 (ar)
BR (1) BRPI0616558B1 (ar)
CA (1) CA2619673C (ar)
GT (1) GT200600421A (ar)
IL (1) IL189015A (ar)
JO (1) JO3684B1 (ar)
NZ (1) NZ566397A (ar)
PE (2) PE20070548A1 (ar)
RU (1) RU2507196C2 (ar)
SG (1) SG165397A1 (ar)
TW (1) TWI386386B (ar)
WO (1) WO2007035718A2 (ar)
ZA (1) ZA200803206B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
BRPI0716261A2 (pt) 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
US20110039930A1 (en) 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
EP4159712B1 (en) * 2020-05-29 2025-03-19 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
CR20230471A (es) * 2021-04-22 2023-11-01 Civi Biopharma Inc Administración oral de oligonucleótidos

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
US5069419A (en) 1989-06-23 1991-12-03 Ic Sensors Inc. Semiconductor microactuator
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH11140064A (ja) * 1997-11-10 1999-05-25 Nippon Nohyaku Co Ltd １，２，３−チアジアゾール誘導体の製造方法及び中間体化合物
US6126140A (en) 1997-12-29 2000-10-03 Honeywell International Inc. Monolithic bi-directional microvalve with enclosed drive electric field
MXPA01008611A (es) * 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
EP1535625B1 (en) * 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
TWI307279B (en) 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
CN1816324A (zh) 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
ES2398237T3 (es) * 2003-07-23 2013-03-14 Novartis Ag Uso de calcitonina en osteoartritis
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006034337A2 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CA2620616C (en) 2005-08-25 2016-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion model of carcinogenesis
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation

Also Published As

Publication number Publication date
NZ566397A (en) 2010-04-30
PE20100241A1 (es) 2010-04-16
SG165397A1 (en) 2010-10-28
ZA200803206B (en) 2009-08-26
RU2008103699A (ru) 2009-10-27
US20130303444A1 (en) 2013-11-14
AU2006292337B8 (en) 2013-02-07
EP1937627A2 (en) 2008-07-02
US9238074B2 (en) 2016-01-19
BRPI0616558B1 (pt) 2021-09-08
US20120065128A1 (en) 2012-03-15
TW200744993A (en) 2007-12-16
CA2619673C (en) 2018-07-10
IL189015A (en) 2016-09-29
EP1937627A4 (en) 2010-09-01
AU2006292337B2 (en) 2012-11-01
RU2507196C2 (ru) 2014-02-20
US8026392B2 (en) 2011-09-27
PE20070548A1 (es) 2007-07-12
AR058053A1 (es) 2008-01-23
CA2619673A1 (en) 2007-03-29
AU2006292337A1 (en) 2007-03-29
WO2007035718A3 (en) 2009-06-18
BRPI0616558A2 (pt) 2011-06-21
GT200600421A (es) 2012-03-16
WO2007035718A2 (en) 2007-03-29
IL189015A0 (en) 2008-08-07
KR20080049128A (ko) 2008-06-03
CN101627011A (zh) 2010-01-13
US20080269108A1 (en) 2008-10-30
JP2009508875A (ja) 2009-03-05
US8431736B2 (en) 2013-04-30
TWI386386B (zh) 2013-02-21
CN105641686A (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
JO2515B1 (ar) الشكل البلوري جاما لهيدروكلوريد الايفابراداين وعملية تحضيره والمكونات الصيدلانية المحتوية عليه
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
UA96449C2 (en) Stable laquinimod preparations
MX2009006055A (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxam il)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoi co.
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
TNSN07452A1 (en) Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
NZ593524A (en) A nonapeptide with anti-tumour activity
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
TW200738714A (en) New secondary amines
ZA200803206B (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
TW200800940A (en) New primary amines
TNSN07228A1 (en) Manufacture process of organic compounds
PL377584A1 (pl) Deuterowane pochodne katecholoaminy oraz środki lecznicze zawierające te związki
TW200621773A (en) Bicyclononene derivatives
ATE366734T1 (de) Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
TW200621774A (en) Bicyclononene derivatives
UA95909C2 (en) Piperidine carboxylic acid amide derivatives
ITMI20040145A1 (it) L-moprololo lpiu' tartrato
TW200518749A (en) Stabilised pharmaceutical compositions